Evidence map›Paper›PMID 38509196›Full record

Trial reportBone marrow transplantation2024

Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial.

Sophie Estran, Michael Loschi, Sami Benachour, Alizée Soldati, Edmond Chiche, Rinzine Sammut, Guillaume Robert, Arnaud Jacquel, Jacques Chibois, Stephane Schneider and 1 more

Abstract readClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sophie Estran *Hematology department, Nice University hospital, Cote d'Azur University, Nice, France.
Michael Loschi *Hematology department, Nice University hospital, Cote d'Azur University, Nice, France.ORCID http://orcid.org/0000-0002-4460-5939
Sami BenachourHematology department, Nice University hospital, Cote d'Azur University, Nice, France.
Alizée SoldatiHematology department, Nice University hospital, Cote d'Azur University, Nice, France.
Edmond ChicheHematology department, Nice University hospital, Cote d'Azur University, Nice, France.
Rinzine SammutHematology department, Nice University hospital, Cote d'Azur University, Nice, France.
Guillaume RobertINSERM U1065, Mediterranean center of molecular medicine, Nice, France.ORCID http://orcid.org/0000-0002-6350-2222
Arnaud JacquelINSERM U1065, Mediterranean center of molecular medicine, Nice, France.
Jacques ChiboisBastide Saint Antoine, Grasse, France.
Stephane SchneiderNutrition department, Nice University hospital, Cote d'Azur University, Nice, France.ORCID http://orcid.org/0000-0001-6256-8169
Thomas CluzeauHematology department, Nice University hospital, Cote d'Azur University, Nice, France. cluzeau.t@chu-nice.fr.ORCID http://orcid.org/0000-0002-6745-1127

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malnutrition increases the risk of non-relapse mortality after allogeneic stem cell transplantation (aHSCT). Here are the results of the ALLONUT clinical trial designed to improve the nutritional outcome of patients receiving aHSCT. ALLONUT is a prospective open label phase 2 clinical trial assessing the efficacy of a close tailored nutritional support and management with traditional and original solutions to improve patients nutritional status following aHSCT. Nutritional status evaluation was performed before transplantation, on Day 0, 30, 100 and one year after transplantation. The study involved 70 patients treated by aHSCT. 10% of patients were moderately or severely malnutrition at baseline and 26.9 were severely malnutrition at D30. Patients' nutritional status improved thanks to the cooking classes and the personalized outpatient nutrition program. At D100, 23% were still malnutrition, while only 10.8% were severely malnutrition one year after transplantation. The QLQ-C30 show that quality of life (QoL) decreased until D30, and improve to reach the pre-transplant level on D100 before exceeding it on D360. The study confirmed that a close, personalized nutritional program combining traditional and original measures can improve both nutritional status and QoL for patients suffering from moderate or severe malnutrition after aHCST.

Indexed as

Hematopoietic Stem Cell TransplantationNutritional StatusQuality of LifeAdultAgedAllograftsFemaleHumansMaleMalnutritionMiddle AgedProspective StudiesTransplantation, Homologous

Identifiers

PMID38509196
PMCPMC11226397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.